Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Hyaline vascular type of unicentric Castleman's disease with proliferation of glomerular endothelial cells.

Wakabayashi K, Asanuma K, Takeda Y, Arakawa A, Osawa I, Horikoshi S, Yao T, Tomino Y.

Clin Nephrol. 2014 Jun;81(6):445-50. doi: 10.5414/CN107705.

PMID:
23211339
2.

Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?

Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, Okino T, Ichimura K, Yoshino T, Makino H.

Am J Kidney Dis. 2004 Jan;43(1):E3-9.

PMID:
14712466
4.

The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.

Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF.

Cancer. 1999 Feb 1;85(3):706-17. Review.

PMID:
10091744
5.

Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.

Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, Ijichi O, Ikarimoto N, Nakata M, Kitajima I, Fukushige T, Takamatsu H, Miyata K, Maruyama I.

Br J Haematol. 1999 Mar;104(3):482-5.

PMID:
10086783
6.

[Expression of interleukin-6 and its clinicopathological significance in Castleman's disease].

Lai YM, Li M, Liu CL, Huang X, Yu GH, Wang XY, Sun L, Chen J, Gao ZF.

Zhonghua Xue Ye Xue Za Zhi. 2013 May;34(5):404-8. doi: 10.3760/cma.j.issn.0253-2727.2013.05.006. Chinese.

PMID:
23688750
7.

Unicentric Castleman's disease of abdomen.

Shah D, Darji P, Lodha S, Bolla S.

J Radiol Case Rep. 2013 Mar 1;7(3):26-33. doi: 10.3941/jrcr.v7i3.1031. Print 2013 Mar.

8.

Treatment of Castleman's disease.

Dispenzieri A, Gertz MA.

Curr Treat Options Oncol. 2005 May;6(3):255-66. Review.

PMID:
15869736
9.

[Clinical and pathological features of Castleman's disease: experience at the Instituto Nacional de Cancerología, Mexico City].

Sobrevilla-Calvo Pde J, Avilés-Salas A, Cortés-Padilla DE, Rivas-Vera S.

Cir Cir. 2009 May-Jun;77(3):187-92. Spanish.

PMID:
19671270
10.

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K.

Blood. 2000 Jan 1;95(1):56-61.

11.

Atypical lymphoproliferative disorders: Castleman's disease. Case report and review of the literature.

Martino G, Cariati S, Tintisona O, Veneroso S, De Villa F, Vergine M, Monti M.

Tumori. 2004 May-Jun;90(3):352-5. Review.

PMID:
15315321
12.

Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.

Lajoie G, Kumar S, Min KW, Silva FG.

Am J Surg Pathol. 1995 Sep;19(9):1021-8.

PMID:
7661275
13.

Secretion of interleukin-6 and vascular endothelial growth factor by spindle cell sarcoma complicating Castleman's disease (so-called 'vascular neoplasia').

Kakiuchi C, Ishida T, Sato H, Katano H, Ishiko T, Mukai H, Kogi M, Kasuga N, Takeuchi K, Yamane K, Fukayama M, Mori S.

J Pathol. 2002 Jun;197(2):264-71.

PMID:
12015752
14.

Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.

Menegato MA, Canelles MF, Tonutti E, Pizzolitto S.

Clin Nephrol. 2004 May;61(5):352-6.

PMID:
15182131
15.

Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease.

Sato Y, Kojima M, Takata K, Morito T, Asaoku H, Takeuchi T, Mizobuchi K, Fujihara M, Kuraoka K, Nakai T, Ichimura K, Tanaka T, Tamura M, Nishikawa Y, Yoshino T.

Mod Pathol. 2009 Apr;22(4):589-99. doi: 10.1038/modpathol.2009.17. Epub 2009 Mar 6.

16.

Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy.

Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, Orita Y, Nakao S, Yoshino T.

J Clin Exp Hematop. 2013;53(1):87-93.

17.

Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases.

Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N.

Pathol Res Pract. 2005;201(4):325-32.

PMID:
15991840
18.

Castleman's disease: A rare lymphoproliferative disorder.

Jongsma TE, Verburg RJ, Geelhoed-Duijvestijn PH.

Eur J Intern Med. 2007 Mar;18(2):87-9.

PMID:
17338958
19.

Isolated microcytic anemia disclosing a unicentric Castleman disease: The interleukin-6/hepcidin pathway?

Vinzio S, Ciarloni L, Schlienger JL, Rohr S, Méchine A, Goichot B.

Eur J Intern Med. 2008 Jul;19(5):367-9. doi: 10.1016/j.ejim.2007.09.006. Epub 2007 Oct 26.

PMID:
18549942
20.

Castleman's disease.

Palestro G, Turrini F, Pagano M, Chiusa L.

Adv Clin Path. 1999 Jan-Apr;3(1-2):11-22. Review.

PMID:
10655569
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk